The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -41.60 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as NEKTAR THERAPEUTICS reports it. History and quarterly detail are in the app.
- Non Cash Royalty Revenue Related To Sale Of Future Royalties$54.9M
- Non Cash Royalties$54.9M
- License Collaboration And Other Revenue$300K
Leadership changes
From NEKTAR THERAPEUTICS's own filings, the day they're filed.
- Sandra Gardiner · Chief Financial Officer · departureeff. 2026-05-15
- Mark A. Wilson · Chief Legal Officer · departureeff. 2025-12-31
- Jillian Thomsen · Chief Financial Officer · departureeff. 2023-04-17
Latest filings
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-08
- 8-K · Company announcement2026-05-07
- DEF 14A · Annual proxy (pay & governance)2026-04-24
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about NEKTAR THERAPEUTICS, every answer cited🔒
- The Intelligence Brief — added when NEKTAR THERAPEUTICS's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.